NEW YORK (360Dx) – Chalmers University of Technology spinout Elypta is developing a metabolism-based liquid biopsy platform for detection and monitoring of cancers, including early detection of recurrent renal cell carcinoma (RCC) after surgery.

Elypta is advancing research, that originated at Chalmers in Gothenburg, Sweden, into the use of glycosaminoglycan metabolites as diagnostic biomarkers for a range of cancer diagnostic applications, the firm's CEO Karl Bergman said in an interview.